tiprankstipranks
Blurbs

NexImmune (NEXI) Gets a Buy from Raymond James

In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on NexImmune (NEXIResearch Report), with a price target of $3.00. The company’s shares closed yesterday at $1.26.

According to TipRanks, Seedhouse is a 4-star analyst with an average return of 6.6% and a 45.28% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as ChemoCentryx, Intercept Pharma, and Arcturus Therapeutics.

Currently, the analyst consensus on NexImmune is a Strong Buy with an average price target of $3.50, which is a 177.78% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $2.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $18.78 and a one-year low of $1.08. Currently, NexImmune has an average volume of 1.19M.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NEXI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ body’s T cells to generate immune response that mimics natural biology. Its creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.

Read More on NEXI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles